# Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

> **NCT07637162** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** AXS-14 (esreboxetine)

## Key facts

- **NCT ID:** NCT07637162
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-04-29
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07637162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07637162, "Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07637162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*